Monday officially kicked-off Multiple Sclerosis (MS) Awareness Week. Because of this, we wanted to take the opportunity to share with you some information about this disease as well as our ongoing commitment to developing a treatment for MS.

For those of you that are not familiar with MS, it is a chronic disease of the central nervous system (CNS) and one of the most common of demyelinating disorders, having a prevalence of approximately 1 per 1000 persons in the United States and Europe. A conservative estimate suggests 300,000 people in the United States are affected by MS, with a global population reaching as many as 3.0 million people.

The disease is characterized primarily by inflammation, demyelination, and axonal injury. In MS, the insulating fatty material surrounding the nerve fibers, known as myelin, which functions to enhance signaling from one end of the nerve cell to the other, is attacked by cells of the immune system causing deficits in signal transduction.

Although the etiology of MS is still unknown, many findings point toward a central role for the immune system in the pathogenesis of the disease. This hypothesis is strongly supported by the beneficial effects of immunomodulatory and immunosuppressive therapy on disease activity. This is where our research fits in.

Many of you may already be familiar with our leading drug candidate, RPI-78M, being studied as a treatment for neurological and autoimmune disorders. Recently, we completed a Phase IIb/IIIa clinical trial using RPI-78M as a treatment for Adrenomyeloneuropathy (AMN). In addition to this research in AMN, we have also been completing, Pre-Clinical, Phase I, and open labels trials using RPI-78M for treating MS.

Through these trials, we have observed promising results showing that RPI-78M has the potential to become one of the most novel treatments for MS. Our observations include the following, all without significant adverse side effects:

• Improved Quality of Life
• Reduced Chronic Fatigue
• Improved Walking Ability
• Greater Strength
• Little Advancement in Disease

As we move through our clinical development program, our focus on RPI-78M and its use as a novel treatment for Multiple Sclerosis (MS) will become a more prominent topic on our website and blog. In the meantime, for those that would like further information about our past published research in Multiple Sclerosis (MS), please feel free to review these links to our peer-reviewed articles:

• Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application (PDF)
• Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins (PDF)

Additional Resources

• National MS Society

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " MS Awareness Week and Our Ongoing Commitment to Treating Multiple Sclerosis (MS)", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

1 Comment

Multiple Sclerosis is a disabling disease, and even if it affects 1% of the total earth population, this doesn’t mean that it shouldn’t be given credit, and that research and fund raising shouldn’t exist for it.

These type of events are always welcomed, because they create social awareness, and raise funds that help the research and the treatment of Multiple Sclerosis. It’s needless to say, that more funds and more research is always welcomed, because only this will allow scientists to find a cure for this disease.

Currently, the liberation therapy and stem cell therapy are somewhat on hold due to lack of funding and interest in the matter. Events like these can help the development of therapies like these ( both very promising and potential cures for MS).

Comment by Multiple Sclerosis — October 2, 2010 @ 10:58 am

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website